Clinical trials: Bronchitis, Acute
Chronic Graft Versus Host Disease, Fasciitis
Glasdegib for Chronic Graft-Versus-Host Disease
This phase I/II trial studies whether glasdegib is helpful in treating sclerosis associated with chronic graft-versus-host disease.
- Trial name
- NCT04111497
- Testing
- Glasdegib
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- Fred Hutchinson Cancer Center
Chronic Graft-versus-host Disease
Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2)
To assess the efficacy of R348 Ophthalmic Solutions administered for 12 weeks to subjects evaluated by objective and subjective measures.
- Trial name
- DROPS-2 (NCT02040623)
- Testing
- R348 Ophthalmic Solution, 0.2%, R348 Ophthalmic Solution, 0.5%
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Rigel Pharmaceuticals
Chronic Low Back Pain
Gait in Low Back Pain Patients After Spinal Mobilization
Introduction: patients with chronic back pain as a result of degenerated disc disease, besides pain also present with impaired gait.
- Trial name
- SpinMob (NCT02645123)
- Testing
- TENS, spinal mobilization, swedish type massage
- Volunteers
- 75 people
- Sponsor
- University of Ioannina
Chronic Obstructive Pulmonary Disease
Long-term Extension Study of the Safety, Tolerability, and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-36)
The purpose of this extension study is to evaluate the long-term safety, tolerability, and efficacy of inhaled aclidinium bromide at two dose levels in patients with moderate to severe chronic obstructive pulmonary disease…
- Trial name
- NCT00970268
- Testing
- Aclidinium bromide
- Where
- 83 sites in United States, Canada
- Volunteers
- 291 people
- Sponsor
- AstraZeneca
Psoriasis
A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis
To evaluate the efficacy of CP-690,550 as compared to etanercept and the safety of CP-690,550 for treatment of moderate to severe chronic plaque psoriasis.
- Trial name
- NCT01241591
- Testing
- CP 690,550 5 mg, CP 690,550 10 mg, Etanercept 50 mg
- Where
- 122 sites in Argentina, Austria and 24 more
- Volunteers
- 1,101 people
- Sponsor
- Pfizer